CD38在临床肿瘤治疗中作用的研究进展

Research progress in the role of CD38 in clinical tumor treatment

肿瘤是全球十大致死原因之一,传统肿瘤的治疗手段有手术治疗、放射治疗和化学治疗。随着针对细胞程序性死亡受体1/细胞程序性死亡-配体1(programmed death 1/programmed cell death 1 ligand 1,PD-1/PD-L1)轴的免疫检查点阻断疗法的发展,实体肿瘤内免疫代谢微环境的变化已被证实是免疫细胞功能天然抑制和免疫治疗获得性抵抗的重要调节因素。CD38作为一个新的靶点产生免疫抑制代谢物(如腺苷)的酶蛋白,可望与免疫治疗相结合运用于临床来提高肿瘤患者的治疗效果,还可作为了解肿瘤免疫治疗响应的指示剂。

Tumor is one of the ten leading causes of death in the world.Traditional tumor treatments include surgery,radiation therapy,and chemotherapy.With the development of immune checkpoint blockade therapy targeting the programmed death 1/programmed cell death 1ligand 1(PD-1/PD-L1)axis,the number of cancers in solid tumors has increased.Changes in the immunometabolic microenvironment have been shown to be important regulators of innate suppression of immune cell function and acquired resistance to immunotherapy.As a new target,CD38 is an enzyme that produces immunosuppressive metabolites(such as adenosine),which can be used in combination with immunotherapy to improve the clinical efficacy of tumor therapy,and can also be used as an indicator for understanding tumor immunotherapy response.